BIOTECHNOLOGY VALUE FUND L P 13D and 13G filings for Corvus Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2022-02-11 7:30 pm Sale | 2021-12-31 | 13G | Corvus Pharmaceuticals, Inc. CRVS | BIOTECHNOLOGY VALUE FUND L P | 1,370,947 3.000% | -1,527,850 (-52.71%) | Filing |
| 2021-02-12 4:09 pm Sale | 2020-12-31 | 13G | Corvus Pharmaceuticals, Inc. CRVS | BIOTECHNOLOGY VALUE FUND L P | 2,898,797 9.990% | -22,380 (-0.77%) | Filing |